Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Int J Mol Sci. 2018 May 15;19(5):1467. doi: 10.3390/ijms19051467.
Circulating microRNAs (miRNAs) hold great potential as novel diagnostic markers for acute coronary syndrome (ACS). This study sought to identify plasma miRNAs that are differentially expressed in young ACS patients (mean age of 38.5 ± 4.3 years) and evaluate their diagnostic potentials. Small RNA sequencing (sRNA-seq) was used to profile plasma miRNAs. Discriminatory power of the miRNAs was determined using receiver operating characteristic (ROC) analysis. Thirteen up-regulated and 16 down-regulated miRNAs were identified in young ACS patients. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) validation showed miR-183-5p was significantly up-regulated (8-fold) in ACS patients with non-ST-segment elevated myocardial infarction (NSTEMI) whereas miR-134-5p, miR-15a-5p, and let-7i-5p were significantly down-regulated (5-fold, 7-fold and 3.5-fold, respectively) in patients with ST-segment elevated myocardial infarction (STEMI), compared to the healthy controls. MiR-183-5p had a high discriminatory power to differentiate NSTEMI patients from healthy controls (area under the curve (AUC) of ROC = 0.917). The discriminatory power for STEMI patients was highest with let-7i-5p (AUC = 0.833) followed by miR-134-5p and miR-15a-5p and this further improved (AUC = 0.935) with the three miRNAs combination. Plasma miR-183-5p, miR-134-5p, miR-15a-5p and let-7i-5p are deregulated in STEMI and NSTEMI and could be potentially used to discriminate the two ACS forms.
循环 microRNAs（miRNAs）作为急性冠状动脉综合征（ACS）的新型诊断标志物具有巨大潜力。本研究旨在鉴定在年轻 ACS 患者（平均年龄 38.5±4.3 岁）中差异表达的血浆 miRNAs，并评估其诊断潜力。采用小 RNA 测序（sRNA-seq）对血浆 miRNAs 进行分析。使用接受者操作特征（ROC）分析确定 miRNA 的判别能力。在年轻 ACS 患者中鉴定出 13 个上调和 16 个下调的 miRNAs。定量逆转录聚合酶链反应（qRT-PCR）验证显示 miR-183-5p 在非 ST 段抬高心肌梗死（NSTEMI）ACS 患者中显著上调（8 倍），而 miR-134-5p、miR-15a-5p 和 let-7i-5p 在 ST 段抬高心肌梗死（STEMI）患者中显著下调（分别为 5 倍、7 倍和 3.5 倍），与健康对照组相比。miR-183-5p 具有区分 NSTEMI 患者与健康对照组的高判别能力（ROC 曲线下面积（AUC）=0.917）。let-7i-5p 对 STEMI 患者的判别能力最高（AUC=0.833），其次是 miR-134-5p 和 miR-15a-5p，三者联合进一步提高（AUC=0.935）。血浆 miR-183-5p、miR-134-5p、miR-15a-5p 和 let-7i-5p 在 STEMI 和 NSTEMI 中失调，可能用于区分两种 ACS 形式。
